TherapeuticsMD Reports Q3 Net Income of $50,000 on $784,000 License Revenue

Reuters

Nov 13, 2025

TherapeuticsMD Reports Q3 Net Income of $50,000 on $784,000 License Revenue

TherapeuticsMD Inc. reported net income from continuing operations of $0.05 million, or $0.00 per basic and diluted common share, for the third quarter of 2025, compared to a net loss of $0.6 million, or $0.05 per share, in the same period of 2024. License revenue, primarily from the Mayne License Agreement, was $0.8 million, up $0.2 million from $0.5 million in the third quarter of 2024. Total operating expenses were $1.6 million, a decrease of 2.1% from the previous year. As of September 30, 2025, cash and cash equivalents totaled $7.1 million. The company continues to evaluate a range of strategic alternatives, including potential acquisitions, mergers, or other strategic transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112021883) on November 12, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583588602"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583588602\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583588602?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583588602","market":"fut","top_or_hot":-1,"title":"TherapeuticsMD Reports Q3 Net Income of $50,000 on $784,000 License Revenue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TherapeuticsMD Reports Q3 Net Income of $50,000 on $784,000 License Revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TXMD\">TherapeuticsMD Inc.</a> reported net income from continuing operations of $0.05 million, or $0.00 per basic and diluted common share, for the third quarter of 2025, compared to a net loss of $0.6 million, or $0.05 per share, in the same period of 2024. License revenue, primarily from the Mayne License Agreement, was $0.8 million, up $0.2 million from $0.5 million in the third quarter of 2024. Total operating expenses were $1.6 million, a decrease of 2.1% from the previous year. As of September 30, 2025, cash and cash equivalents totaled $7.1 million. The company continues to evaluate a range of strategic alternatives, including potential acquisitions, mergers, or other strategic transactions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112021883) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TherapeuticsMD Reports Q3 Net Income of $50,000 on $784,000 License Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTherapeuticsMD Reports Q3 Net Income of $50,000 on $784,000 License Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 05:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TherapeuticsMD Reports Q3 Net Income of $50,000 on $784,000 License Revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TXMD\">TherapeuticsMD Inc.</a> reported net income from continuing operations of $0.05 million, or $0.00 per basic and diluted common share, for the third quarter of 2025, compared to a net loss of $0.6 million, or $0.05 per share, in the same period of 2024. License revenue, primarily from the Mayne License Agreement, was $0.8 million, up $0.2 million from $0.5 million in the third quarter of 2024. Total operating expenses were $1.6 million, a decrease of 2.1% from the previous year. As of September 30, 2025, cash and cash equivalents totaled $7.1 million. The company continues to evaluate a range of strategic alternatives, including potential acquisitions, mergers, or other strategic transactions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112021883) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXMD","symbol_name":"TherapeuticsMD Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL7M8wsT:1","article_id":"2583588602","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583588602","pubTimestamp":1762981676,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TherapeuticsMD Inc. reported net income from continuing operations of $0.05 million, or $0.00 per basic and diluted common share, for the third quarter of 2025, compared to a net loss of $0.6 million, or $0.05 per share, in the same period of 2024. License revenue, primarily from the Mayne License Agreement, was $0.8 million, up $0.2 million from $0.5 million in the third quarter of 2024. Total operating expenses were $1.6 million, a decrease of 2.1% from the previous year. As of September 30, 2025, cash and cash equivalents totaled $7.1 million. The company continues to evaluate a range of strategic alternatives, including potential acquisitions, mergers, or other strategic transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TXMD":"TherapeuticsMD Inc.","BK4007":"制药"},"translate_title":"TherapeuticsMD报告第三季度净利润为50,000美元，许可收入为784,000美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXMD":0.9},"content_text":"TherapeuticsMD Reports Q3 Net Income of $50,000 on $784,000 License Revenue\n    \n\nTherapeuticsMD Inc. reported net income from continuing operations of $0.05 million, or $0.00 per basic and diluted common share, for the third quarter of 2025, compared to a net loss of $0.6 million, or $0.05 per share, in the same period of 2024. License revenue, primarily from the Mayne License Agreement, was $0.8 million, up $0.2 million from $0.5 million in the third quarter of 2024. Total operating expenses were $1.6 million, a decrease of 2.1% from the previous year. As of September 30, 2025, cash and cash equivalents totaled $7.1 million. The company continues to evaluate a range of strategic alternatives, including potential acquisitions, mergers, or other strategic transactions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112021883) on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}